VEGF-C potentiates immunotherapy to eradicate GBM

• Unlike VEGF-A, VEGF-C promotes lymphangiogenesis
• VEGFC-AAV pre-treatment in mice results in complete rejection of brain tumors.
• VEGFC-mRNA treatment after tumor establishment potentiates anti-PD1 therapy in mice, results in 100% survival
• Lower tumor burden correlates with higher survival in mice

Pending Patents: PRV filed 62/768,390, US/PCT to be filed

Innovators: Akiko Iwasaki, Ph.D.